Pharmaceuticals

Pancreatic Cancer Drugs Market Expansion Outlook: $4.7 Billion by 2029 Forecast

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Pancreatic Cancer Drugs Market Between 2025 And 2029?

The pancreatic cancer drugs market has seen consistent growth in recent years. It is projected to expand from $3.97 billion in 2024 to $4.07 billion in 2025, achieving a compound annual growth rate (CAGR) of 2.4%. Historically, this market expansion can be linked to robust economic growth in developing markets, a growing elderly population, and the rising prevalence of pancreatic cancer.

The pancreatic cancer drugs market size is anticipated to undergo consistent expansion over the coming years. Its valuation is projected to reach $4.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.7%. This expansion during the forecast period is primarily driven by rising cancer incidence rates, increased healthcare expenditure, and enhanced government backing. Prominent trends expected in this period include a strong focus on developing new treatments for pancreatic cancer, a push towards novel nanomedicine therapies, a commitment to boosting investments, an emphasis on strategic collaborations, and a drive for product innovations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2565&type=smp

Which Drivers Are Supporting Growth Of The Pancreatic Cancer Drugs Market?

The rising incidence of pancreatic cancer is anticipated to propel the expansion of the pancreatic cancer drugs market. As the volume of pancreatic cancer cases increases, the demand for related medications is also expected to climb, which will further stimulate the growth of the pancreatic cancer drugs market. This increase in cancer cases is primarily attributed to an aging global population and a growing number of individuals battling obesity. For illustration, data from the American Cancer Society indicates that in 2023, an estimated 64,050 people (including 33,130 men and 30,920 women) were projected to be diagnosed with pancreatic cancer, and approximately 50,550 individuals (composed of 26,620 men and 23,930 women) were expected to die from it.

What Are The Different Segment Classifications Within The Pancreatic Cancer Drugs Market?

The pancreatic cancer drugs market covered in this report is segmented –

1) By Type: Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs

2) By Drug Combination: Single, Double, Triplet, Quadruplet

3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users

Subsegments:

1) By Pancreatic Neuroendocrine Cancer Drugs: Somatostatin Analogs, Targeted Therapy Drugs, Chemotherapy Agents

2) By Pancreatic Exocrine Cancer Drugs: Chemotherapy Agents, Targeted Therapy Drugs, Immunotherapy Drugs

How Are Trends Influencing The Pancreatic Cancer Drugs Market?

A significant ongoing trend in the pancreatic cancer drugs market is the shift towards combination therapy over monotherapy. Major industry players acknowledge that combining two or more drugs offers an effective method to boost drug efficacy, thereby enhancing the survival rate for patients diagnosed with pancreatic cancer. Companies investing in this combination therapy include Rafael Pharmaceuticals, which announced the start of its Pivotal Phase 3 Trial (AVENGER 500) for CPI-613 (delimitate) alongside Modified FOLFIRINOX as a primary treatment for individuals with Metastatic Pancreatic Cancer. Furthermore, Apexigen, Inc., a clinical-stage biopharmaceutical company, presented new clinical data on APX005M when used in combination therapy for patients with metastatic pancreatic cancer.

Which Key Market Players Are Investing In Expansion And Innovation Of Pancreatic Cancer Drugs Market?

Major companies operating in the pancreatic cancer drugs market include Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, Abbvie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd, Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt Ltd, Apikos Pharma, GlaxoSmithKline Plc, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer AG, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Which Geographies Are Emerging As Strong Markets For The Pancreatic Cancer Drugs Industry?

North America was the largest region in the pancreatic cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Pancreatic Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2565&type=smp

Browse Through More Reports Similar to the Global Pancreatic Cancer Drugs Market 2025, By The Business Research Company

Diuretics Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito Urinary Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795